Floatz logo

Mtm-H-001

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Cancer Institute and Hospital, Chinese Academy of Medical SciencesUNKNOWNN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

202 Active assets in the Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma cohort.

Asset / SponsorPhaseRating
Etoposide
Weill Medical College of Cornell University
Phase 2BBB
Chlorambucil
Ascentage Pharma Group Inc.
Phase 4BBB
Lisaftoclax
Henan Cancer Hospital
Phase 3BBB
Prednisone
AstraZeneca
Phase 3BBB
Irinotecan
IGM Biosciences, Inc.
Phase 2BBB

View all 50 →

Same molecule, other indications

Mtm-H-001 is also rated in:

follicular lymphomaActive
D
Indicative · N/A
30 / 100
View asset →
mantle cell lymphomaActive
D
Indicative · N/A
30 / 100
View asset →
diffuse large B-cell lymphomaActive
D
Indicative · N/A
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →